Active, not recruitingPhase 3NCT02170090
Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Biliary Tract Cancer
Studying Cholangiocarcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
- Principal Investigator
- Henning WegeUniversitätsklinikum Hamburg-Eppendorf
- Intervention
- Gemcitabine(drug)
- Enrollment
- 789 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2014 – 2025
Study locations (30)
- Bankstown Hospital, Bankstown, New South Wales, Australia
- Nepean Hospital Cancer Care, Kingswood, New South Wales, Australia
- St. George Hospital, Kogarah, New South Wales, Australia
- Prince of Wales Hospital, Randwick, New South Wales, Australia
- Calvary Mater Newcastle, Waratah, New South Wales, Australia
- Townsville Hospital, Douglas, Queensland, Australia
- Royal Brisbane and Women's Hospital, Herston, Queensland, Australia
- Princess Alexandra Hospital, Woolloongabba, Queensland, Australia
- Flinders Medical Centre, Bedford Park, South Australia, Australia
- Fiona Stanley Hospital Perth, Murdoch, Western Australia, Australia
- Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia
- St. John of God, Subiaco, Western Australia, Australia
- Kaiser-Franz-Josef Hospital, Vienna, Austria
- Vejle Hospital, Vejle, Denmark
- University Medical Center Hamburg-Eppendorf, Hamburg, Free and Hanseatic City of Hamburg, Germany
- +15 more locations on ClinicalTrials.gov
Collaborators
Deutsche Krebshilfe e.V., Bonn (Germany) · Cancer Research UK · Australasian Gastro-Intestinal Trials Group · Dutch Cancer Society
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02170090 on ClinicalTrials.govOther trials for Cholangiocarcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07478523FAPI-PET Value for the Initial Screening of Pancreatic and Biliary CancersUniversity Hospital, Bordeaux
- RECRUITINGNANCT07476651Scout Dose of Resin MicrospheresSeoul National University Hospital
- RECRUITINGPHASE2NCT06728410A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or RearrangementMehmet Akce
- RECRUITINGPHASE2NCT07223307REGULUS: MRI-guided Adaptive SABR for Liver CancersStanford University
- RECRUITINGPHASE2NCT07201519Study of Safety/Feasibility of a Hybrid Model of Tertiary and Community Delivery of Hepatic Artery Infusion ChemotherapyMichael J Cavnar, MD
- RECRUITINGPHASE2NCT07260175Phase II Study Evaluating Ivosidenib Maintenance After SOC Adjuvant Chemotherapy in Curative mIDH1 CholangiocarcinomaInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
- RECRUITINGNANCT06735560Study Assessing PET Imaging With Zirconium-labelled Girentuximab in Patients With HCC, ICC or NENNantes University Hospital
- RECRUITINGNCT07206355In-Depth Characterisation of Biliary Strictures and Hepato-Pancreato-Biliary Focal Lesions for Development of New Technologies to Tackle Hepato-Pancreato-Biliary CancersUniversity of Nottingham